Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Antimicrobial Agents and Chemotherapy
Boubakar B BaClaudine Quentin

Abstract

The influence of antibiotic dosages and bacterial mutator phenotypes on the emergence of linezolid-resistant mutants was evaluated in an in vitro pharmacokinetic-pharmacodynamic model. A twice-daily 0.5-h infusion of a 200-, 600-, or 800-mg dose for 48 h was simulated against four strains (MIC, 2 microg/ml): Staphylococcus aureus RN4220 and its mutator derivative MutS2, Enterococcus faecalis ATCC 29212, and a mutator clinical strain of E. faecalis, Ef1497. The peak concentrations (4.38 to 4.79, 13.4 to 14.6, and 19.2 to 19.5 microg/ml) and half-lives at beta-phase (5.01 to 6.72 h) fit human plasma linezolid pharmacokinetics. Due to its bacteriostatic property, the cumulative percentages of the dosing interval during which the drug concentration exceeded the MIC (T > MIC), 66.6 and 69.1% of the dosing interval, were not significant, except for Ef1497, with an 800-mg dose and a T > MIC of 80.9%. At the standard 600-mg dosage, resistant mutants (2- to 8-fold MIC increases) were selected only with Ef1497. A lower, 200-mg dosage did not select resistant mutants of E. faecalis ATCC 29212, but a higher, 800-mg dosage against Ef1497 did not prevent their emergence. For the most resistant mutant (MIC, 16 microg/ml), characterization of ...Continue Reading

References

Oct 2, 1981·JAMA : the Journal of the American Medical Association·P D Ellner, H C Neu
Apr 1, 1996·Antimicrobial Agents and Chemotherapy·G E ZurenkoS J Brickner
Aug 29, 1998·The Journal of Biological Chemistry·L WorthS Clark
May 17, 2001·Antimicrobial Agents and Chemotherapy·T GeeR Wise
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·X Zhao, K Drlica
Dec 19, 2001·Lancet·D J Diekema, R N Jones
Dec 26, 2001·Journal of Bacteriology·Erick DenamurIvan Matic
Apr 30, 2002·International Journal of Antimicrobial Agents·Niels Frimodt-Møller
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Anne-Laure PrunierRoland Leclercq
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·S H MarshallL B Rice
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·Franziska SchaaffGabriele Bierbaum
Oct 31, 2002·The Journal of Antimicrobial Chemotherapy·Olaf BurkhardtHartmut Lode
Nov 7, 2002·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J G SlatterS Yamazaki
Nov 26, 2002·The Journal of Infectious Diseases·Satish K PillaiHoward S Gold
Jul 16, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ian ChopraKeith Miller
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Michael LobritzLouis B Rice
Oct 18, 2003·The Journal of Antimicrobial Chemotherapy·Bulent BozdoganPeter C Appelbaum
Nov 14, 2003·The Journal of Antimicrobial Chemotherapy·Antina BargerBernd Wiedemann
Mar 12, 2004·International Journal of Antimicrobial Agents·Bülent Bozdogan, Peter C Appelbaum
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·Markus MüllerHartmut Derendorf
Mar 18, 2005·The Journal of Antimicrobial Chemotherapy·Johan W MoutonGeorge L Drusano
May 4, 2005·Journal of Bacteriology·Anne-Laure Prunier, Roland Leclercq
May 27, 2005·Antimicrobial Agents and Chemotherapy·Pejman DehghanyarChristian Joukhadar
May 30, 2006·The Pediatric Infectious Disease Journal·Susanne M RobertsAdrian M Zelazny
Jan 24, 2007·Antimicrobial Agents and Chemotherapy·Lauren M BoakRoger L Nation
Apr 17, 2007·The Journal of Infectious Diseases·Nadège Bourgeois-NicolaosFlorence Doucet-Populaire
May 8, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Boubakar B BaMarie-Claude Saux
Jan 24, 2008·Antimicrobial Agents and Chemotherapy·Silke BesierThomas A Wichelhaus
Feb 5, 2008·The Journal of Antimicrobial Chemotherapy·Stephen H ZinnerAlexander A Firsov

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.